ECOG-ACRIN EA9161

Primary Category:

Treatment Protocols

Disease Category:

Chronic Lymphocytic Leukemia, Leukemia

Status:

Open

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

NCT#03701282

Eligible for screening study DCP 001

EQ9161 Quality of Life (QOL) component has reach accrual goal.  Therefore,  EFFECTIVE August 5, 2020, the QOL component is closed to new accrual.